title: Real life treatment of diabetes mellitus type 2 patients: an analysis based on a large sample of 394,828 German patients.
abstract: OBJECTIVE
  The aim of this claims-based data analysis was to describe the care of German T2DM patients and to determine which subgroups could be differentiated in terms of the achieved T2DM-related treatment results, the underlying comorbidities, and the achieved comorbidity-related treatment results.
  
  
  METHODS
  We included all T2DM patients insured by a large sickness fund in 2010/2011. We defined 12 subgroups according to observed HbA1C, blood pressure and Charlson Comorbidity Index (CCI). For each subgroup, available sociodemographic and clinical information were reported. Different treatment variables were described. T2DM-related events leading to acute hospitalisations were reported.
  
  
  RESULTS
  We included 394,828 T2DM patients in our analysis; for 228,703 patients' detailed data as basis for subgroup classification were available. For 4.5% of these patients, a HbA1C >9% was observed. 21,833 of the T2DM patients were affected by a T2DM-related event; the risk was 5.53% per patient year; 1.74% of the patients suffered from more than one event. Most frequent event types were hospitalisation with T2DM as primary diagnosis (2.39%), vascular interventions/stent implantations (1.92%), and ischaemic stroke (1.19%). There were significant differences between the observed subgroups in terms of T2DM-related event risk.
  
  
  CONCLUSIONS
  Overall, our data indicate that the typically treated T2DM patient has a number of comorbidities and thus treatment focused solely on T2DM is neither possible nor clinically meaningful. Particularly those patients who reached HbA1C goals, but had also achieved relevant additional treatment goals reached low yearly T2DM event rates whereas subgroups failing to achieve one or several treatment goals are facing much higher event risks.
authors.affiliation: Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Hochschule Wismar, Germany. Electronic address: Thomas.wilke@hs-wismar.de.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wilke
authors.affiliation: Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Hochschule Wismar, Germany.
authors.forename: Antje
authors.initials: A
authors.lastname: Groth
authors.affiliation: AOK PLUS, Dresden, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Fuchs
authors.affiliation: Novo Nordisk Pharma GmbH, Germany.
authors.forename: Lisa
authors.initials: L
authors.lastname: Seitz
authors.affiliation: Novo Nordisk Pharma GmbH, Germany.
authors.forename: Joachim
authors.initials: J
authors.lastname: Kienhöfer
authors.affiliation: Diabeteszentrum Erfurt/Bad Berka, Germany.
authors.forename: Rainer
authors.initials: R
authors.lastname: Lundershausen
authors.affiliation: AOK PLUS, Dresden, Germany.
authors.forename: Ulf
authors.initials: U
authors.lastname: Maywald
mesh_terms: D000368:Aged; D015331:Cohort Studies; D015897:Comorbidity; D066264:Datasets as Topic; D048909:Diabetes Complications / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D015995:Prevalence; D016896:Treatment Outcome
keywords: Micro- and macrovascular events; Patient profiles; Real life treatment; Type 2 diabetes mellitus